BioXcel Therapeutics, Inc. (Nasdaq: BTAI) announced its financial results for the fourth quarter and full year ended December 31, 2025, highlighting a net revenue of $256,000 for Q4 and $642,000 for the full year, a decrease from $366,000 and $2.3 million in the previous year, respectively. The company is preparing for the potential approval of IGALMI in the at-home setting for treating acute agitation associated with bipolar disorders and schizophrenia. A supplemental New Drug Application (sNDA) was submitted to the FDA in January, with expectations for approval as early as year-end 2026. The company is also advancing its commercial strategy based on a comprehensive market assessment, which indicates a significant opportunity in the at-home treatment market. CEO Vimal Mehta emphasized the successful year for the company and the focus on expanding IGALMI's market reach, alongside ongoing development in Alzheimer's dementia treatments. Despite a net loss of $12.5 million for Q4 and $69.9 million for the full year, the company remains optimistic about its future prospects and cash position of $28.8 million as of December 31, 2025.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.